ClinicalTrials.gg
CompletedNCT02218047CONTI-PVUpdated Jun 1, 2021

AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.

A Phase 3 interventional study of Pegylated-Proline-interferon alpha-2b and Best available therapy (BAT) in Polycythemia Vera, sponsored by AOP Orphan Pharmaceuticals AG. Completed at 47 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-01.

Sponsored by AOP Orphan Pharmaceuticals AG · Phase 3, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing ropeginterferon alfa-2b in Polycythemia Vera — 1 open to participants now, 3 under way, 2 of them phase 3. ropeginterferon alfa-2b · Polycythemia Vera.

Enrollment
2nd of 11
170 · median 49
Started
2014
the only one that year
Phase 3
6 of 11
1 open now
Registered
3rd of 11
by date
Lead sponsor
4 of 11
AOP Orphan Pharmaceuticals AG

Among the 11 studies testing ropeginterferon alfa-2b in Polycythemia Vera, this one is the 2nd largest by enrollment, is the only one that started in 2014, is one of 6 in phase 3, and was the 3rd registered.

Polycythemia Vera

279 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

1 of the 11 studies testing ropeginterferon alfa-2b in Polycythemia Vera is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ropeginterferon alfa-2b

ropeginterferon alfa-2b: first FDA approval 2021 (BESREMI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing ropeginterferon alfa-2b in Polycythemia Vera, or all of them as a file.
02

Study summary

Polycythemia Vera (PV) is a disease of bone marrow stem cells that manifests in a drastic increase of red blood cells and frequently also of white blood cells. The "thickening" of the blood in relation with a modified function of the cells has several consequences like increased blood pressure, pruritus of the skin, fatigue, disturbed blood circulation in the brain as well as fingers and toes and an increased risk of arterial and venous thrombosis (thrombosis is the formation of a blood clot in a vessel); like stroke, cardiac infarction, deep vein thrombosis in the legs. In case of a strong increase of platelets there is an additional risk of bleedings. As the disease progresses the size of spleen and liver increased in most cases and the bone marrow shows signs of fibrosis. In some cases of PV a progression at a later time point to a leukemia (increased formation of white blood cells) can occur.

The aim of this study is to show that the study drug AOP2014 (pegylated proline interferon alpha-2b) has the long term efficacy and safety in controlling the disease. A comparison arm is receiving best available therapy as selected by the investigator. Response to the treatment is measured by several blood parameters as well as size of the spleen.

Interferon-alpha has been shown to be effective in controlling the blood parameters by immunologically influencing the blood building cells. This can lead to a suppression of the disease-causing stem cells and help healthy stem cells to proliferate. Through this mechanism it is possible that Interferon-alpha can avoid long-term damaging effects of the disease.

Read the detailed description

This is a Phase III, parallel-arm, open-label continuation of the PROUD-PV study performed in adults diagnosed with Polycythemia Vera (PV). Patients who received AOP2014 in the primary study, PROUD-PV will continue on AOP2014, patients who received HU in the PROUD-PV study will receive best available therapy as selected by the investigator. Only patients who completed PROUD-PV including the end of study visit will be enrolled into this continuation study.

03

Conditions studied

  • Polycythemia Vera

Keywords

  • Pegylated-Proline-interferon alpha-2b (AOP2014)
  • Polycythemia Vera
  • PROUD-PV
  • CONTINUATION-PV
  • AOP Orphan
  • Polycythemia
  • Hematologic Diseases
  • Myeloproliferative Disorders
  • Bone Marrow Diseases
  • Interferon-alpha
  • Peginterferon alfa-2b
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who completed the 12 months AOP2014 treatment arm of the PROUD-PV study and at the "end-of-treatment visit" (EoT) of the PROUD-PV study who fulfill at least one of the following criteria:

    • normalization of at least two out of three main blood parameters (Hct, PLTs and WBCs) if these parameters were moderately increased (Hct\<50%, WBC\<20 x 109/L, PLTs\<600 x 109/L) at baseline of the PROUD-PV study, OR
    • >35% decrease of at least two out of three main blood parameters (Hct, PLTs and WBCs) if these parameters were massively increased (Hct>50%, WBCs>20 x 109/L, PLTs>600 x 109/L), at baseline of the PROUD-PV study, OR
    • normalization of spleen size, if spleen was enlarged at baseline of the PROUD-PV study, OR
    • otherwise a clear, medically verified benefit from treatment with AOP2014 (e.g. normalization of disease-related micro-vasculatory symptoms, substantial decrease of JAK2 allelic burden).
  2. Signed written ICF.

Exclusion criteria

Exclusion criteria:

Withdrawal criteria, as specified in the PROUD-PV study, which mandate treatment discontinuation:

  1. Non-recovery from the AOP2014 related toxicities to the grade (usually, Grade I) which allows continuation of the treatment.
  2. HADS score of 11 or higher on either or both of the subscales, and /or development or worsening of the depression or suicidal thoughts.
  3. Progressive and clinically significant increase of liver enzyme levels despite dose reduction, or if such increase is accompanied by increased level, any signs or symptoms of a clinically significant disease.
  4. Clinically significant development of a new ophthalmologic disorder, or worsening of a pre-existing one, during the study.
  5. Loss of efficacy of AOP2014 or any comparable situation where no further benefits of treatment continuation are expected by the investigator.

The main efficacy evaluation criterion will be disease response defined as Hct\<45% without phlebotomy (at least 3 months since the last phlebotomy), PLTs\<400 x 109/L, WBCs\<10 x 109/L, and normal spleen size.

The main efficacy endpoint will be the maintenance rate of disease response at assessment visits (every three months).

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (actual)

Study arms

  • Active comparator
    Best available therapy (BAT)

    Best available therapy, as chosen by the investigator for patients who had been on HU in the 1 Year PROUD-PV study

    Drug: Best available therapy (BAT)

  • Experimental
    Pegylated-Proline-interferon alpha-2b

    AOP2014 for those patients who had been on AOP2014 in the PROUD-PV study

    Drug: Pegylated-Proline-interferon alpha-2b

Interventions

  • DrugRopeginterferon alfa-2bStudies of Ropeginterferon alfa-2bRopeginterferon alfa-2b pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.

    Also known as: AOP2014

  • DrugBest available therapy (BAT)

    Best available therapy as selected by the investigator

    Also known as: best available therapy

06

What researchers measure

Primary outcomes

  1. Disease response at quarterly assessment visits

    The primary efficacy endpoint will be the rate of disease response at assessment visits (every 3 months). The co-primary efficacy evaluation criterion will be (1) disease response defined as hematologic response: Hct\<45% without phlebotomy (at least 3 months since the last phlebotomy), PLTs\<400 x 109/L, WBCs\<10 x 109/L, and normal spleen size, and (2) disease response defined as hematologic response (Hct\<45% without phlebotomy (at least 3 months since the last phlebotomy), PLTs\<400 x 109/L, WBCs\<10 x 109/L), resolution and/or clinically improvement of disease-related signs (clinical significant splenomegaly) and disease-related symptoms (microvascular disturbances, pruritus, headache).

    Time frame: 3 years

07

Study locations

47 sites
  • LKH Graz
    Graz, Austria
  • University Hospital Innsbruck
    Innsbruck, Austria
  • Elisabethinen Hospital Linz
    Linz, Austria
  • Salzburg Regional Hospital
    Salzburg, Austria
  • Hanusch Hospital
    Vienna, Austria
  • Medical University Vienna
    Vienna, Austria
  • Hospital Wels-Grieskirchen
    Wels, Austria
  • University Multiprofile Hospital for Active Treatment "Sveti Georgi", Plovdiv
    Plovdiv, Bulgaria
  • Specialized Hospital for Active Treatment of Hematological Diseases
    Sofia, Bulgaria
  • Multiprofile Hospital for Active Treatment "Sveta Marina", Varna
    Varna, Bulgaria
  • Multiprofile Hospital for Active Treatment - Hristo Botev, Vratsa, First Department of Internal Medicine
    Vratsa, Bulgaria
  • University Hospital Brno
    Brno, Czechia
  • University Hospital Hradec Kralove
    Hradec Kralove, Czechia
  • University Hospital Kralovske Vinohrady
    Prague, Czechia
  • University Hospital Motol
    Prague, Czechia
  • Institute Paoli-Calmettes
    Marseille, France
  • Hospital Saint-Louis
    Paris, France
  • Clinical Research Center CIC
    Poitiers, France
  • Aachen University Hospital, Medical Clinic IV
    Aachen, Germany
  • University Hospital Bonn, Center for Internal Medicine, Medical Clinic and Outpatient Clinic III
    Bonn, Germany
  • University Hospital Carl Gustav Carus, Medical Clinic and Polyclinic I
    Dresden, Germany
  • St Istvan and St Laszlo Hospital of Budapest
    Budapest, Hungary
  • University of Debrecen
    Debrecen, Hungary
  • Bekes County Pandy Kalman Hospital, 1st Department of Medicine, Hematology
    Gyula, Hungary
  • Kaposi Mor County Teaching Hospital
    Kaposvar, Hungary
  • University of Szeged, Albert Szent-Gyorgyi Clinical Center, Koranyi fasor 6
    Szeged, Hungary
  • University Hospital in Cracow
    Krakow, Poland
  • Independent Public Teaching Hospital No.1 in Lublin
    Lublin, Poland
  • Fryderyk Chopin Provincial Specialized Hospital
    Rzeszow, Poland
  • Nicolaus Copernicus Municipal Specialist Hospital
    Torun, Poland
  • Institute of Hematology and Transfusion Medicine
    Warsaw, Poland
  • Emergency Clinical County Hospital Brasov
    Brasov, Romania
  • Bucharest University Emergency Hospital
    Bucharest, Romania
  • Coltea Clinical Hospital
    Bucharest, Romania
  • Baranov Republican Hospital
    Petrozavodsk, Russian Federation
  • Samara Kalinin Regional Clinical Hospital
    Samara, Russian Federation
  • Komi Republican Oncology Center
    Syktyvkar, Russian Federation
  • Tula Regional Clinical Hospital
    Tula, Russian Federation
  • Yaroslavl Regional Clinical Hospital
    Yaroslavl, Russian Federation
  • University Hospital with Outpatient Clinic F.D. Roosevelt
    Banska Bystrica, Slovakia
  • Saint Cyril and Metod University Hospital Bratislava
    Bratislava, Slovakia
  • Hospital del Mar
    Barcelona, Spain
  • Cherkasy Regional Oncology Center, Regional Treatment and Diagnostics Hematology Center
    Cherkasy, Ukraine
  • Dnipropetrovsk City Multispecialty Clinical Hospital #4
    Dnipropetrovsk, Ukraine
  • National Research Center for Radiation Medicine, Institute of Clinical Radiology
    Kiev, Ukraine
  • Institute of Blood Pathology and Transfusion Medicine
    Lviv, Ukraine
  • O.F. Herbachevskyi Regional Clinical Hospital
    Zhytomyr, Ukraine
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2014 to primary completion in Apr 2021, 77 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2014
First posted
Aug 15, 2014
StartActual
Nov 2014
Primary completionActual
Apr 29, 2021
CompletionActual
Apr 29, 2021
Last update
Jun 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02218047
Lead sponsor
AOP Orphan Pharmaceuticals AG
Collaborators
PharmaEssentia Corporation (for the U.S.)
Responsible party
Sponsor
First posted
Aug 15, 2014
Start date
Nov 2014
Primary completion
Apr 29, 2021
Completion
Apr 29, 2021
Last update
Jun 1, 2021

Study contacts

Heinz Gisslinger, MD
principal investigator · Med Uni Wien

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropeginterferon alfa-2b

Start the discussion